GLP-1 drugs have 'little or no effect' on risk of obesity-related cancers, study suggests

Popular weight-loss drugs “probably have little or no effect” on a person’s risk of developing one of the 13 obesity-related ...
BioSpace

Lilly Cuts Zepbound Prices, Again, When Buying Through DTC Program

Following Novo Nordisk’s price cuts for its own GLP-1 medicines, Eli Lilly is offering discounts for the obesity drug ...
Devdiscourse

Race in Obesity Drugs Heats Up Amidst Legal Battles and Aid Crises

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

Lilly Cuts Low-Dose Zepbound Price for Cash-Pay Buyers

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...
Fierce Pharma

Lilly joins Novo in GLP-1 self-pay price cuts, lowering costs of single-dose Zepbound vials

In the early November announcement of its agreement with the government, Lilly pledged to reduce the self-pay price of ...

Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...
PopCulture.com

Tan France Talks ‘Bittersweet’ Ending of ‘Queer Eye’ and Using Fashion to Reduce Stigma About Obesity (Exclusive)

Tan France is using his experience in fashion way beyond styling. Now, the Queer Eye staple is partnering with Lilly, the ...